Skip to main content

2025 IDWeek Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Session Icons

Live Streamed

On Demand

Eva Fernvik, PhD

ViiV Healthcare, Sweden

Disclosure(s): GSK: Stocks/Bonds (Public Company); ViiV Healthcare: Stocks/Bonds (Private Company)

Poster(s):

(P-357) The Global REGAL cohort: A REtrospective real-world study of the effectiveness and tolerability of the antiretroviral treatment reGimens DTG/3TC compAred to BIC/FTC/TAF in older persons Living with HIV

Monday, October 20, 2025
12:15 PM - 1:30 PM US ET
(P-360) Real-world Effectiveness and Safety Outcomes in People with HIV-1 Switching to Dolutegravir + Lamivudine (DTG + 3TC) with Unknown Prior Genotype: a Systematic Literature Review and Meta-analysis

Monday, October 20, 2025
12:15 PM - 1:30 PM US ET